Journal Article

No Effect of Pyridoxine on the Incidence of Myelosuppression during Prolonged Linezolid Treatment

D. Plachouras, E. Giannitsioti, S. Athanassia, F. Kontopidou, A. Papadopoulos, K. Kanellakopoulou and H. Giamarellou

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 43, issue 9, pages e89-e91
Published in print November 2006 | ISSN: 1058-4838
Published online November 2006 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/508280
No Effect of Pyridoxine on the Incidence of Myelosuppression during Prolonged Linezolid Treatment

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.

Journal Article.  1819 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.